ImmunityBio Inc (IBRX) concluded trading on Wednesday at a closing price of $3.16, with 14.32 million shares of worth about $45.26 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -41.80% during that period and on January 29, 2025 the price saw a gain of about 2.60%. Currently the company’s common shares owned by public are about 696.83M shares, out of which, 75.81M shares are available for trading.
Stock saw a price change of -1.86% in past 5 days and over the past one month there was a price change of 17.47%. Year-to-date (YTD), IBRX shares are showing a performance of 23.44% which decreased to -3.95% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.28 but also hit the highest price of $10.53 during that period. The average intraday trading volume for ImmunityBio Inc shares is 6.12 million. The stock is currently trading 12.14% above its 20-day simple moving average (SMA20), while that difference is down -11.38% for SMA50 and it goes to -35.33% lower than SMA200.
ImmunityBio Inc (NASDAQ: IBRX) currently have 696.83M outstanding shares and institutions hold larger chunk of about 9.44% of that.
The stock has a current market capitalization of $2.31B and its 3Y-monthly beta is at 0.81. It has posted earnings per share of -$0.89 in the same period. It has Quick Ratio of 2.64. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBRX, volatility over the week remained 10.35% while standing at 10.24% over the month.
Stock’s fiscal year EPS is expected to rise by 30.00% while it is estimated to increase by 16.77% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on January 10, 2025 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by Piper Sandler stated ImmunityBio Inc (IBRX) stock as a Neutral in their note to investors on May 12, 2023, suggesting a price target of $4 for the stock.
